By Colin Kellaher

 

Merck & Co. on Monday said it agreed to buy clinical-stage biopharmaceutical company Imago BioSciences Inc. in a $1.35 billion cash deal that bolsters Merck's hematology portfolio.

Kenilworth, N.J., drugmaker Merck said it would pay $36 a share for Imago, more than double Friday's closing price of $17.40 for the South San Francisco, Calif., company.

Imago is a developing new medicines for the treatment of myeloproliferative neoplasms and other bone-marrow diseases. The company's lead product candidate, bomedemstat, is in multiple Phase 2 studies for the treatment of essential thrombocythemia, myelofibrosis and polycythemia vera.

Merck said it expects to complete the acquisition of Imago in the first quarter of 2023.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

November 21, 2022 07:14 ET (12:14 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Imago BioSciences (NASDAQ:IMGO)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024 Plus de graphiques de la Bourse Imago BioSciences
Imago BioSciences (NASDAQ:IMGO)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024 Plus de graphiques de la Bourse Imago BioSciences